Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics

Cited by (416)

Items 401–416 of 416

1. Clonal determinants of organotropism and survival in metastatic uveal melanoma
   Bailey S.C.L. Jones, Emma A. Hammes, Patrick Christopher Demkowicz, Mitchelle Matesva, Renelle Pointdujour‐Lim, John H. Sinard, Antonietta Bacchiocchi, Ruth Halaban, Marcus Bosenberg, Mario Sznol et al. · 2026 · npj Precision Oncology
2. Multi-Model Deep Learning Framework for Brain Tumor Classification Using MRI and Genomic Data
   S Jayesh, Sophia S · 2025 · International Conference for Advancement in Technology (ICONAT)
3. Schlafen 11 (SLFN11) overexpression in multiple myeloma and nucleolar translocation in response to bortezomib
   Yasuhiro Arakawa, Daiki Taniyama, Kazuhito Suzuki, Shingo Yano, Yves G. Pommier · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
4. Protocol for quantifying interaction patterns among genomic alterations in cancer
   Adrian Maqueda Real, Seokjin Ham, Laia Ollé-Monràs, Solip Park · 2026 · STAR Protocols
5. Comprehensive genetic profiling of malignant odontogenic tumors in a Japanese cohort using multi-gene panel testing
   Takeru Kobayashi, Norihisa Ichimura, Yusuke Urata, Ryo Ebata, Hideharu Hibi · 2026 · Journal of Oral and Maxillofacial Surgery Medicine and Pathology
6. Agent-Driven Validation of Oncology Therapeutic Targets
   Kuan-Lin Huang · 2026 · bioRxiv
7. Gene coordination patterns across 8,314 tumors reveal a spectral point of no return in cancer progression
   John D. Mayfield · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
8. An overview of targeted drug delivery systems specific for fibroblast growth factor receptors and their co-receptors
   Krzysztof Ciura, Natalia Porębska, Ł. Opaliński · 2026 · Expert Opinion on Drug Delivery
9. BRAF-amplified glioblastoma patients have a worse prognosis than those with BRAF mutation and are associated with amplification of MET, RHEB and CUL1
   Rong Da, Maode Wang, Haitao Jiang, Wei Wang · 2026 · BMC Neurology
10. Development and linguistic validation of the German “Multidimensional Impact of Cancer Risk Assessment” ( MICRA ) questionnaire
    Yvonne Mergel, Joelle Ronez, Fabian Ecke, Johanna Tecklenburg, Petra Anders, Scarlett Winterfeld, Stephanie Stiel, Stefanie Wolters, Paul Cella, Beate Vajen · 2026 · Journal of Genetic Counseling
11. Tumor-node response heterogeneity: Exploring the “spatial biology” of neoadjuvant therapy response in rectal cancer and its clinical implications
    Rui-Gang Wang · 2026 · World Journal of Gastroenterology
12. Pan-cancer signaling landscape linked to endothelial and immune Sphingosine-1-phosphate receptor 1 (S1PR1) expression
    Yazmin Torres-Santos, Yarely Mabell Beltrán‐Navarro, Guadalupe Reyes‐Cruz, José Vázquez‐Prado · 2026 · In Silico Pharmacology
13. GMHAN: a heterogeneous graph attention framework for prioritizing coding and non-coding driver genes
    Ping Meng, Tianjiao Zhang, Guohua Wang · 2026 · Bioinformatics
14. Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib
    Yasuhiro Arakawa, Daiki Taniyama, Kazuhito Suzuki, Shingo Yano, Yves G. Pommier · 2026 · Cancer Research Communications
15. An In Vitro and In Vivo Assessment of the Anti‐Breast Cancer Activity of Erythrina excelsa Baker (Fabaceae) Bark Extracts
    Jonas Walantini, Marius Trésor Kemegne Sipping, Merline Ymele Nguedia, Roland Nhouma Rebe, Abel Joël Gbaweng Yaya, Derek Tantoh Ndinteh, Dieudonné Njamen, Stéphane Zingue · 2026 · Cancer Reports
16. Genomic and Clinical Disparities Among Racial Groups In Ovarian Serous Cystadenocarcinoma
    Salamatu Mikailu Ibrahim, Zakariyya Muhammad Bello, Sharafudeen Dahiru Abubakar · 2026 · Indian Journal of Gynecologic Oncology